Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; none of the 26 sources its claims cite is checked for support yet.

The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis

Open access

Abstract

There is interest in the role of peripheral interleukin-6 (IL-6) in depression and the effect of treatment (e. g., pharmacologic, psychosocial, neurostimulation). However, the relationship between cognitive behavioral therapy (CBT), IL-6 and depression has not yet been established. We conducted a meta-analysis to explore the association between CBT and change of peripheral IL-6 levels in depressive symptoms or major depressive disorder (MDD). A systematic search of online databases (i.e., PubMed, Web of Science, Google Scholar, PsycINFO, and Cochrane Library) was completed from inception to May 2021. In total, 10 eligible papers with 940 participants reporting peripheral IL-6 levels before and after CBT were included in the analysis. The main result indicates that peripheral levels of IL-6 were significantly lower after CBT intervention in individuals with depression, with a small effect (SMD = 0.38, 95% CI: 0.07, 0.69, p = 0.02). The results of subgroup analyses demonstrate that (1) there was a significant decrease in IL-6 for studies that were equal to or <8 weeks in duration vs. more than 8 weeks in duration, and (2) IL-6 was significantly reduced in the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis (i.e., DSM-IV, DSM-IV-TR, or DSM-V) of MDD, but not for the subgroup without DSM diagnosis. Publication year was identified as a potential contributor to heterogeneity of the results from our analysis. Taken together, our findings support the notion that CBT influences peripheral IL-6 in individuals with depression and represents a point of commonality with other antidepressant treatment modalities (e.g., antidepressants). Systematic Review Registration: https://doi.org/10.17605/osf.io/tr9yh, identifier: 10.17605/osf.io/tr9yh.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis found that peripheral IL-6 levels were significantly lower after CBT in individuals with depression, with a small pooled effect. Subgroup analyses suggested the effect was significant for CBT duration ≤8 weeks and for DSM-diagnosed MDD, while publication year contributed to heterogeneity.

Key findings

  • Across 10 studies and 940 participants, peripheral IL-6 was significantly lower after CBT intervention, with a small effect (SMD = 0.38, 95% CI: 0.07, 0.69, p = 0.02); heterogeneity was high (p < 0.00001; I² = 79%).
  • Subgroup analysis by treatment duration found a significant decrease in IL-6 for studies ≤8 weeks (SMD = 0.86, 95% CI: 0.49, 1.23, p < 0.00001), but no significant difference for studies >8 weeks (p > 0.05).
  • Subgroup analysis by diagnosis found a significant decrease in the DSM diagnosis subgroup (SMD = 0.41, 95% CI: 0.01, 0.80, p = 0.05), but not in the subgroup without DSM diagnosis (p > 0.05).
  • Meta-regression identified publication year as a statistically significant contributor to heterogeneity (β = −0.49, 95% CI = −0.88, −0.09, t = −2.86, p = 0.02; adjusted R² = 52.91%); no publication bias was detected by Egger’s test (p = 0.208) or Begg’s test (p = 0.180).

Methods

  • Systematic search of PubMed, Web of Science, Google Scholar, PsycINFO, and Cochrane Library from inception to May 2021, plus reference-list searching, for studies reporting peripheral IL-6 before and after CBT in adults with depression.
  • Included 10 eligible papers with 940 participants; inclusion required adults ≥18 years with DSM-defined MDD or a verified scale for depressive symptoms, pre/post CBT IL-6 levels, and RCT, open-label, or longitudinal pre-test–post-test designs.
  • Pooled analysis used Review Manager 5.4.1 and Stata 12.0; because of high heterogeneity, a random-effects model was used, with SMD and 95% CI, plus subgroup analyses, meta-regression, sensitivity analysis, Egger’s/Begg’s tests, and GRADE quality assessment.

Limitations

  • The paper states that the sample size was relatively small (only 10 eligible studies), that included studies had varying definitions of depression and five included subthreshold depression, that sensitivity analysis indicated insufficient stability, that limited information prevented thorough analysis of heterogeneity sources, that residual confounding could not be controlled, and that prior antidepressant treatment may affect IL-6 but medication status could not be distinguished.
  • Evident from the text: heterogeneity was high in the main analysis (I² = 79%), one study did not report treatment duration, one did not include sex, and one did not mention the IL-6 measure method.
  • Evident from the text: the review pools heterogeneous designs and populations, including RCTs and pre-post studies, and cannot determine whether the CBT–IL-6 relationship is causal, predictive, or moderational.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2022.844176

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of the article extraction process, including the reasons for exclusion.
Figure 1 Summary of the article extraction process, including the reasons for exclusion.CC BY · PubMed Central
Figure 2 Forest plot for change in IL-6 before and after CBT.
Figure 2 Forest plot for change in IL-6 before and after CBT.CC BY · PubMed Central
Figure 3 Forest plot for change in IL-6 before and after CBT with CBT intervention duration of 8 weeks.
Figure 3 Forest plot for change in IL-6 before and after CBT with CBT intervention duration of 8 weeks.CC BY · PubMed Central
Figure 4 Forest plot for change in IL-6 before and after CBT under different depression diagnosis method.
Figure 4 Forest plot for change in IL-6 before and after CBT under different depression diagnosis method.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 16 Not checked · 39 Own results and interpretations

24 more claims

Create a free account to see all 55 claims and to verify the 26 references still open.

See all claims — free account
  • It may state two separate claims as one. 9
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • Consistentz = 1.34reported p = .18 · recomputed p = .180

    “z = 1.34, p = .180”

1 of 1

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 53 references

Cited by

See all 22

Metadata

Authors
Ma, H., Xu, J., Li, R., McIntyre, R. S., Teopiz, K. M., Cao, B., & Yang, F.
Affiliations
  • Southwest University (CN)
  • University of Toronto (CA)
Corresponding author
  • Cao, Bing
  • Yang, Fahui
Venue
Frontiers in Psychiatry
Published
2022-05-13
Volume
13
Pages
844176-844176
ISSN
1664-0640 (ISSN-L)
OpenAlex
W4280551526
Cited by
22
References
53
Citations by year
2026: 6 · 2025: 8 · 2024: 5 · 2023: 2 · 2022: 1
FWCI
0.28
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Ministry of Education, India
  • Southwest University (SWU019039)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
cognitive behavioral therapy, interleukin-6, depression, major depressive disorder, psychosocial interventions, antidepressant effects, treatment duration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.3389/fpsyt.2022.844176
The paper
Ma, H., Xu, J., Li, R., McIntyre, R. S., Teopiz, K. M., Cao, B., & Yang, F. (2022). The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.844176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.